Skip to content

Released Nov 10, 2025, before the open

10-Q filed Nov 10, 2025, 41 days after period end · 0002023658-25-000109

Q3 2025 · 10-Q
Revenue—
Net Income-$36.33MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.67N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$40,676,000N/M
Operating Cash Flowderived-$29,248,000N/M
Free Cash Flowderived-$29,290,000N/M

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023
Net Income-$36.33M-$17.48M-$22.85M
EPS Diluted-$0.67-$1.60-$38.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR